Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1288-1294

  Howard, Orion M ^a   Gribben, John G ^a   Neuberg, Donna S ^a   Grossbard, Michael ^a   Poor, Christina ^a   Janicek, Milos J ^a   Shipp, Margaret A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; MANTLE CELL LYMPHOMA; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIGOR; SEPSIS; STRIDOR; WHEEZING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN D1; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; IMMUNOGLOBULINS; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDNISOLONE; REMISSION INDUCTION; VINCRISTINE;

EID: 0036499084     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1288     Document Type: Article

References (48)

1. Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome
2. Mantle cell lymphoma: A population-based clinical study
3. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories) - A Southwest Oncology Group study
4. Patterns of survival in mantle-cell lymphoma
5. Mantle cell lymphoma: A clinicopathologic study of 80 cases
6. Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors
7. Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients
8. Mantle cell lymphoma: A retrospective study on 27 patients. Clinical features and natural history
9. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group
10. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma
11. "Small" B-cell non-Hodgkin's lymphomas with splenomegaly at presentation are either either mantle cell lymphoma or marginal zone cell lymphoma: A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis
12. Bone marrow and peripheral blood involvement in mantle cell lymphoma
13. Intermediate lymphocytic lymphoma of the small intestine: Mantle cell lymphoma
14. Mantle cell lymphoma: A retrospective study of 121 cases
15. Retrospective analysis of mantle cell lymphoma: Experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL)
16. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
17. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
18. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20 year period
19. Mantle cell lymphoma: A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
20. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group
21. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma
22. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma
23. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission
24. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
25. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
26. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
27. Peripheral blood stem cell contamination in mantle cell non-Hodgkin's lymphoma: The case for purging?
28. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation
29. CD20: A regulator of cell-cycle progression of B-lymphocytes
30. Mantle cell lymphoma: A clinicopathological study of 55 cases
31. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma
32. The utility of flow cytometric immunophyenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma
33. Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma
34. Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23
35. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20
36. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
37. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
38. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
39. Real-time 5′→3′ exonuclease-based PCR assay for detection of the t(11;14)(q13;14)(q13;q32)
40. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas
41. Mantle cell lymphoma: Rapid polymerase chain reaction-based genotyping of a morphologically heterogeneous entity
42. Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues
43. An improved method for detection of B-lymphoid clonality by polymerase chain reaction
44. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
45. Simple and rapid preparation of samples for PCR
46. Avoiding false positives with PCR
47. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
48. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma